2022-12-012022-12-012021-07-22Gudiol, C., Durà-Miralles, X., Aguilar-Company, J., Hernández-Jiménez, P., Martínez-Cutillas, M., Fernandez-Avilés, F.,...,Carratalà, J. (2021). Co-infections and superinfections complicating COVID-19 in cancer patients: a multicentre, international study. Journal of Infection, 83 (3), 306-313. https://doi.org/10.1016/j.jinf.2021.07.014.0163-4453https://hdl.handle.net/11441/140045Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with COVID-19. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted at least 48 h were included in the analysis of superinfections. Results: 684 patients were included (384 with solid tumors and 300 with hematological malignancies). Co-infections and superinfections were documented in 7.8% (54/684) and 19.1% (113/590) of patients, re- spectively. Lower respiratory tract infections were the most frequent infectious complications, most of- ten caused by Streptococcus pneumoniae and Pseudomonas aeruginosa . Only seven patients developed op- portunistic infections. Compared to patients without infectious complications, those with infections had worse outcomes, with high rates of acute respiratory distress syndrome, intensive care unit (ICU) admis- sion, and case-fatality rates. Neutropenia, ICU admission and high levels of C-reactive protein (CRP) were independent risk factors for infections. Conclusions: Infectious complications in cancer patients with COVID-19 were lower than expected, affect- ing mainly neutropenic patients with high levels of CRP and/or ICU admission. The rate of opportunistic infections was unexpectedly low. The use of empiric antimicrobials in cancer patients with COVID-19 needs to be optimized.application/pdf8 p.engAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Co-infectionsCOVID-19Cancerinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess10.1016/j.jinf.2021.07.014